Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The EVICEL® Gastrointestinal Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ethicon, Inc.
ClinicalTrials.gov Identifier:
NCT01589822
First received: April 30, 2012
Last updated: February 24, 2015
Last verified: February 2015
Results First Received: July 16, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Subject);   Primary Purpose: Treatment
Condition: Gastrointestinal Diseases
Intervention: Biological: EVICEL Fibrin Sealant

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
EVICEL Fibrin Sealant: Randomized

EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen.

EVICEL Fibrin Sealant: Intraoperative

Standard of Care Standard surgical technique for GI anastomosis.
Experimental: EVICEL Fibrin Sealant: Non-Randomized

EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen

EVICEL Fibrin Sealant: Intraoperative


Participant Flow:   Overall Study
    EVICEL Fibrin Sealant: Randomized   Standard of Care   Experimental: EVICEL Fibrin Sealant: Non-Randomized
STARTED   84   89   41 
COMPLETED   80   86   40 
NOT COMPLETED   4   3   1 
Withdrawal by Subject                1                2                0 
Death                1                0                0 
Missed 90 day visit                2                1                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Subjects enrolled who consented and were randomized into the study or assigned to the non-randomized portion and had the investigational product applied were included in the analysis sets. The Safety Set consists of 125 subjects treated with EVICEL (41 Non- Randomized) and 89 subjects treated with Standard of Care.

Reporting Groups
  Description
EVICEL Fibrin Sealant: Randomized

EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen.

EVICEL Fibrin Sealant: Intraoperative

Standard of Care Standard surgical technique for GI anastomosis.
Experimental: EVICEL Fibrin Sealant: Non-Randomized

EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen

EVICEL Fibrin Sealant: Intraoperative

Total Total of all reporting groups

Baseline Measures
   EVICEL Fibrin Sealant: Randomized   Standard of Care   Experimental: EVICEL Fibrin Sealant: Non-Randomized   Total 
Overall Participants Analyzed 
[Units: Participants]
 84   89   41   214 
Age 
[Units: Years]
Mean (Standard Deviation)
 61.1  (11.1)   62.5  (10.8)   62.0  (12.2)   61.8  (11.1) 
Gender 
[Units: Participants]
       
Female   41   33   21   95 
Male   43   56   20   119 
Race (NIH/OMB) 
[Units: Participants]
       
American Indian or Alaska Native   0   0   0   0 
Asian   21   21   8   50 
Native Hawaiian or Other Pacific Islander   0   0   0   0 
Black or African American   0   0   1   1 
White   61   65   31   157 
More than one race   0   0   0   0 
Unknown or Not Reported   2   3   1   6 
Region of Enrollment 
[Units: Participants]
       
United States   15   17   13   45 
Canada   2   2   4   8 
Belgium   17   17   3   37 
Australia   10   9   6   25 
New Zealand   10   10   1   21 
United Kingdom   10   14   7   31 
Korea, Republic of   20   20   7   47 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Absence of Gastrointestinal (GI) Leak   [ Time Frame: 40 days ]

2.  Secondary:   Incidence of Adverse Events   [ Time Frame: up to Day 90 ]

3.  Secondary:   Incidence of GI Leak   [ Time Frame: 90 days ]

4.  Secondary:   Incidence of Stricture   [ Time Frame: up to Day 90 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Director of Clinical Development
Organization: Ethicon
phone: 1 908 218-2492
e-mail: JBatill2@its.jnj.com



Responsible Party: Ethicon, Inc.
ClinicalTrials.gov Identifier: NCT01589822     History of Changes
Other Study ID Numbers: 400-11-002
Study First Received: April 30, 2012
Results First Received: July 16, 2014
Last Updated: February 24, 2015
Health Authority: United States: Food and Drug Administration
Korea: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Belgium: Federal Agency for Medicinal Products and Health Products
Canada: Health Canada
New Zealand: Medsafe